Cortexyme Inc
CRTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.96M
Close$
$4.32
121.6% upside
Current Fair Value
121.6% upsideUndervalued by 121.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.96 Million |
|---|---|
| Enterprise Value | $-104,021,952.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.68 |
| Beta | 1.4 |
| Outstanding Shares | 6,132,845 |
Return
| Return on Equity | 261.79% |
|---|---|
| Return on Assets | -74.58% |
| Return on Invested Capital | -110.08% |
Valuation & Multiples
| P/E Ratio | -0.48 |
|---|---|
| PEG | -0.13 |
| Price to Sales | - |
| Price to Book Ratio | 0.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.36 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.5806▲ 258.06% |
|---|---|
| Total Calls | 31,000▲ 119.86% |
| Total Puts | 80,000▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 37.34%▲ 15.48% |
|---|---|
| Total Invested | $67.48M▲ 251.06% |
| Investors Holding | 69▲ 23.00% |
ESG Score
No data
About Cortexyme Inc
38 employees
CEO: Dirk Thye Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Pha...